STOCK TITAN

SOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2022 on August 9, 2022

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) will announce its financial results for Q2 2022 on August 9, 2022, before U.S. markets open. The company will host a conference call at 8:30 a.m. EDT to discuss these results and the business outlook. The conference call will be available for live streaming on their Investor Relations website, with a replay to follow. SOPHiA GENETICS is focused on data-driven medicine and serves over 790 institutions globally with its SOPHiA DDM™ Platform, which analyzes multimodal data for healthcare and research purposes.

Positive
  • The SOPHiA DDM™ Platform has been adopted by over 790 institutions worldwide, indicating strong market acceptance.
Negative
  • None.

BOSTON and LAUSANNE, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal 2022 before U.S. markets open on Tuesday, August 9, 2022. SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:30 a.m. EDT / 2:30 p.m. CEST.

The call will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be available on the website after its completion.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by over 790 hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn and Instagram. Where others see data, we see answers.

Investor Contact:
Jennifer Pottage
Head of Investor Relations
Jpottage@sophiagenetics.com

Media Contact:
Don Granese
Public Relations
Dgranese@sophiagenetics.com


FAQ

When will SOPHiA GENETICS release its Q2 2022 financial results?

SOPHiA GENETICS will release its Q2 2022 financial results on August 9, 2022.

What time is the SOPHiA GENETICS conference call for financial results?

The conference call will begin at 8:30 a.m. EDT on August 9, 2022.

How can I access the SOPHiA GENETICS financial results conference call?

The conference call will be webcast live on the SOPHiA GENETICS Investor Relations website.

What is SOPHiA GENETICS known for?

SOPHiA GENETICS is known for its SOPHiA DDM™ Platform, which facilitates data-driven medicine.

How many institutions use the SOPHiA DDM™ Platform?

Over 790 hospitals, laboratories, and biopharma institutions use the SOPHiA DDM™ Platform globally.

SOPHiA GENETICS SA Ordinary Shares

NASDAQ:SOPH

SOPH Rankings

SOPH Latest News

SOPH Stock Data

205.96M
62.57M
5.82%
53.4%
0.09%
Health Information Services
Healthcare
Link
United States of America
Rolle